What amount sold does Pacific Diabetes Technologies, Inc. report in Form D filings?

The latest linked filings report $7M sold across 4 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Pacific Diabetes Technologies, Inc.'s most recent SEC filing?

Pacific Diabetes Technologies, Inc.'s most recent Form D filing was on 2025-11-17.

How many investors does Pacific Diabetes Technologies, Inc. have?

The most recent Form D filing lists 15 investor(s).

What type of securities does Pacific Diabetes Technologies, Inc. offer?

Pacific Diabetes Technologies, Inc.'s SEC Form D filings indicate debt offerings.

Pacific Diabetes Technologies, Inc.

CIK: 0001835476·Biotechnology·PORTLAND, OR·Corporation·Founded 2021

Reported Sold

$6,982,533

Total Filings

Identified Offerings

Last Filed

Nov 17, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Nov 17, 2025Form D/A — Amendment

Reported sold: $3,385,000 · Target: $3,500,000

Rule 506(b)·15 investors

Changed: Reported amount sold, Offering target, Reported investors

Oct 20, 2025Form D — New notice

Reported sold: $2,920,000 · Target: $3,000,000

Rule 506(b)·4 investors

Mar 14, 2025Form D — New notice

Reported sold: $2,057,533 · Target: $5,000,000

Rule 506(b)·5 investors

Sep 9, 2024Form D/A — Amendment

Reported sold: $1,540,000 · Target: $5,000,000

Rule 506(b)·17 investors

Changed: Reported amount sold, Reported investors

Sep 13, 2023Form D — New notice

Reported sold: $500,000 · Target: $5,000,000

Rule 506(b)·1 investor

Jun 2, 2021Form D — New notice

Reported sold: $0 · Target: $2,000,000

Rule 506(b)·0 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

33%

Latest reported sold across 4 identified offerings

$6,982,533

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Thomas Seidel

Related Person

Appears on 3 filings

Hank Wuh

Related Person

Appears on 3 filings

Christopher Marsh

Related Person

Appears on 3 filings

Peter Eckenberg

Related Person

Appears on 3 filings

Thomas Seidl

Related Person

Appears on 3 filings

Yobie Benjamin

Related Person

Appears on 2 filings

Edward La Cava

Related Person

Appears on 2 filings

Ken Ward

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 17, 2025	Amendment	$3,500,000	$3,385,000	15
Oct 20, 2025	New	$3,000,000	$2,920,000	4
Mar 14, 2025	New	$5,000,000	$2,057,533	5
Sep 9, 2024	Amendment	$5,000,000	$1,540,000	17
Sep 13, 2023	New	$5,000,000	$500,000	1
Jun 2, 2021	New	$2,000,000	$0	0

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Swep Bio, Inc.

Biotechnology

Offering target: $4,999,976

Filed Oct 29, 2026